Eisai Signs a Research Agreement with Cerveau Technologies for its Novel Tau Imaging Agent

 Eisai Signs a Research Agreement with Cerveau Technologies for its Novel Tau Imaging Agent

Eisai Signs a Research Agreement with Cerveau Technologies for its Novel Tau Imaging Agent

Shots:

  • Eisai & Cerveau Technologies enter into a research collaboration to utilize Cerveau’s [F-18]MK-6240 in PET scan for assessing the status of neurofibrillary tangles (NFTs) in the brain
  • The focus of the collaboration is to utilize Cerveau’s [F-18]MK-6240 as a biomarker and to evaluates its effect in Eisai’s neurodegenerative research studies
  • Cerveau’s MK-6240 is a positron emission tomography (PET) used to scans neurofibrillary tangles (NFTs) in the brain. Cerveau Technologies also collaborated with Enigma Biomedical & Sinotau Pharmaceutical for its imaging agent

Click here to read full press release/ article | Ref: BusinessWire | Image: Bizjournals

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post